Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367807 · ClinicalTrials.gov registry record
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
A clinical trial of HIV, sponsored by Philadelphia Fight.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT02367807 is a study of HIV that has completed, run by Philadelphia Fight. The registered enrollment target is 50 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02367807, a study of HIV, has completed, sponsored by Philadelphia Fight.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 48-week prospective observational study that will allow testing of the hypothesis that a program in which pre-exposure prophylaxis (PrEP) is administered to young men of color who have sex with men (yMSMc) in a community youth drop-in center in conjunction with a multifaceted behavioral intervention as well as standard HIV prevention interventions can achieve at least 70% retention, as well as a medication adherence rate significantly better than that previously reported in the literature. The proposed program evaluation can provide critical information for the enhancement and scale-up of successful PrEP programs at FIGHT and elsewhere in an effort to make PrEP available to a growing number of persons at risk of acquiring human immunodeficiency virus (HIV).
Conditions Studied
Interventions
- DRUG Emtricitabine and tenofovir disoproxil fumarate
Study Locations (1)
Pennsylvania
- Philadelphia FIGHT - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367807
The ClinicalTrials.gov registry entry for NCT02367807 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower). The listed sponsor is Philadelphia Fight, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Emtricitabine and tenofovir disoproxil fumarate is the first listed.
NCT02367807 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02367807 about?
NCT02367807 is a clinical study titled "PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color". This is a 48-week prospective observational study that will allow testing of the hypothesis that a program in which pre-exposure prophylaxis (PrEP) is administered to young men of color who have sex with men (yMSMc) in a community youth drop-in center in conjunction with a multifaceted behavioral in...
What is the current status of trial NCT02367807?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2015-02. Estimated completion is 2016-08.
What conditions does trial NCT02367807 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT02367807?
The interventions under investigation include: Emtricitabine and tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT02367807?
This trial is sponsored by Philadelphia Fight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367807 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.